emtricitabine + tenofovir disoproxil fumarate + T101

This combination therapy is being evaluated for the treatment of chronic hepatitis B (CHB) and consists of the therapeutic vaccine **T101** administered alongside the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) **emtricitabine** and **tenofovir disoproxil fumarate**. T101 is a recombinant adenovirus serotype 5 (Ad5) viral vector vaccine developed by Tasly Tianjin Biopharmaceutical, utilizing Transgene's TG1050 technology platform. It is engineered to express three essential hepatitis B virus (HBV) antigens—polymerase, core, and surface antigens—to stimulate a robust, multi-specific T-cell response aimed at achieving a functional cure. Emtricitabine and tenofovir disoproxil fumarate (often administered as the fixed-dose combination Truvada) serve as potent antiviral agents that inhibit HBV DNA polymerase, thereby suppressing viral replication. The combination strategy aims to reduce the viral load while simultaneously re-educating the host immune system to recognize and clear HBV-infected hepatocytes.

Brand names

Truvada

Other names

Therapeutic Hepatitis B Adenovirus Injection + emtricitabine + tenofovir disoproxil fumarateT101 Combined With Nucleoside AnaloguesT-101 Combined With Nucleoside AnaloguesT 101 Combined With Nucleoside Analogues